Tag: Biotech and Pharma

Lilly, Walmart launch first retail pick-up option for weight-loss drug

Eli Lilly (LLY.N), said on Wednesday it is partnering with Walmart (WMT.N), to expand access to Lilly’s weight-loss drug Zepbound, which will be offered for pick-up at Walmart pharmacies nationwide by mid-November.

Eli Lilly, Novo Nordisk Stocks Drop. Trump Targets Ozempic, ‘Fat Loss’ Drug Prices.

Eli Lilly and Novo Nordisk stocks fell sharply early Friday after President Donald Trump suggested the price of blockbuster weight-loss medicines could come down substantially.

Abbott revenue falls short of estimates on weak demand for diagnostic devices

Abbott missed analysts’ estimates for third-quarter revenue on Wednesday, as weakness in its diagnostics and nutritional businesses failed to offset strong demand for its medical devices, sending its shares down 3% premarket.

Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push

Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing competition from generic drugs.

Pfizer does deal with Trump on prescription drug prices

 Pfizer (PFE.N) and President Donald Trump on Tuesday said they had cut a deal in which the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid program to what it charges in other developed countries in exchange for tariff relief.

Pfizer expands obesity drug pipeline with $7.3 billion deal to buy Metsera

 Pfizer (PFE.N), said on Monday it would acquire weight-loss drug developer Metsera (MTSR.O), in a deal valued at up to $7.3 billion, including future payments, to secure its position in the lucrative obesity treatment market.

Όμιλος Lavipharm: Άνοδος 29,4% στα αναπροσαρμοσμένα EBITDA

Ο Όμιλος Lavipharm παρουσιάζει σημαντική αύξηση των ενοποιημένων πωλήσεων το α΄εξάμηνο σύμφωνα με τα οικονομικά αποτελέσματα που δημοσίευσε.

Eli Lilly cautious on using FDA fast-track voucher for weight-loss pill

Eli Lilly’s international president said on Wednesday it was too early to assume the company would use the U.S. Food and Drug Administration’s new fast-track review process for its experimental weight-loss pill orforglipron.

Novo Nordisk flags drug trial promise amid hunt for next weight-loss blockbuster

Novo Nordisk on Wednesday flagged promising late-stage trial results for its new Cagrilinitide obesity treatment, as the Danish pharmaceutical giant seeks a next-generation alternative to its blockbuster Wegovy weight-loss drug.

Novo Nordisk stock rises after EU approves heart benefit label for Rybelsus

Novo Nordisk A/S (NYSE:NVO) stock rose 2.8% in Monday’s premarket trading after the European Medicines Agency approved an update to the Rybelsus label to include cardiovascular benefits for patients with type 2 diabetes.

Wegovy-maker Novo Nordisk to cut around 9,000 jobs

Danish pharmaceutical giant Novo Nordisk on Wednesday announced plans to cut around 9,000 roles, or roughly 11.5% of its global workforce.

Novartis to acquire Tourmaline Bio for $1.4 billion

Novartis (NOVN.S), will acquire Tourmaline Bio (TRML.O), for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday.

Lilly’s blood cancer drug meets main goal in late-stage study

Eli Lilly’s (LLY.N), blood cancer treatment Jaypirca helped patients live longer without the disease getting worse, the U.S. drugmaker said on Monday, meeting the main goal in a late-stage study in previously untreated patients.

Novo’s Wegovy Beats Lilly’s Zepbound for Heart Health, Study Finds. What It Means for Stocks.

Novo Nordisk’s (NOVO.B) Wegovy cut the risk of heart attacks, stroke and death by more than Eli Lilly’s (LLY) weight-loss drug Zepbound, a new study found.

Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown

Denmark on Friday slashed its annual growth forecast to 1.4% from 3%, in large part due to weaker expectations for pharmaceutical giant Novo Nordisk.

Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval

Eli Lilly on Tuesday said its daily weight loss pill helped patients with obesity and Type 2 diabetes shed weight in a late-stage trial, meeting the study’s main goal and clearing the way for the company to file for approval of the drug globally.

Drugmaker Novo Nordisk freezes hiring for non-critical jobs

Wegovy-maker Novo Nordisk (NOVOb.CO), has implemented a global hiring freeze covering job roles that are not critical for its business, the company said on Wednesday.

A Tweak to Medicare is Good for Merck. Can It Cure the Troubled Stock?

A new tweak to Medicare’s drug price negotiation program will allow Merck to squeeze more revenue out of its cancer blockbuster Keytruda. The question is whether it will be enough to make a difference for the troubled stock.

US FDA approves Tonix Pharma’s drug to manage pain related to chronic condition

The U.S. Food and Drug Administration has approved Tonix Pharmaceuticals’ (TNXP.O), drug to manage pain related to a type of chronic condition called fibromyalgia, the company said on Friday.

Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease

Shares of  Novo Nordisk climbed almost 5% Monday after the company’s blockbuster Wegovy obesity drug received accelerated approval from the U.S. Food and Drug Administration to treat a serious liver disease.